LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the publication of data from a pivotal Phase III clinical trial of ZYFLO CRTM (zileuton) extended-release tablets in the June 2007 issue of the Journal of Asthma. ZYFLO CR was approved by the U.S. Food and Drug Administration (FDA) on May 30, 2007. Critical Therapeutics, together with its co-promotion partner Dey, L.P. (DEY), expects to begin marketing ZYFLO CR in the U.S. in the fall of 2007. ZYFLO CR and the immediate release formulation of zileuton, ZYFLO® (zileuton tablets), are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. ZYFLO CR and ZYFLO are not indicated for use in the reversal of bronchospasm in acute asthma attacks, but can be continued during acute exacerbations of asthma.
